Brennan's golden handshake could total $65M

As usual with pharma CEO departures, the first wave of talk is all about the simple facts--who and how and why. Next? The gossip about severance. In David Brennan's case, word is that he's due for a golden handshake of up to £40 million, or $65 million, from AstraZeneca ($AZN). Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.